Hospira profit beats estimates on higher prices, sales

November 6, 2014 7:19 PM

3 0

(Reuters) - Hospira Inc reported a quarterly profit that handily beat analysts' estimates as the company raised prices and sold more of its injectable drugs.

The drugmaker's performance is closely watched by investors for the impact of generic competition on its injectable sedative, Precedex.

Also read: Actelion shares plunge on report it eyes "complicated" J&J deal

Read more

To category page